Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/LSD/Immunology & Inflammation

LSD for Immunology & Inflammation

14 papers and 0 clinical trials exploring lsd as a treatment for immunology & inflammation.

Compoundclassic psychedelic

LSD

LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM120 have reignited clinical development.

Full LSD profile
IndicationOver 264 million people worldwide suffer from depression, with a significant subset experiencing related inflammatory conditions.

Immunology & Inflammation

Recent research highlights the potential of psychedelics, particularly psilocybin and MDMA, in modulating immune responses and inflammation, shedding light on their therapeutic implications for mood disorders and other immune-related conditions. Studies are beginning to uncover the mechanisms through which these compounds exert anti-inflammatory effects and promote neuroplasticity, particularly in the context of major depressive disorder (MDD).

Full Immunology & Inflammation profile

Academic Research

14 papers
Paywallindividual

Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD

This case report (n=3) documents the first academic instances of olfactory improvement after psychedelic use. The study also discusses potential mechanisms, such as serotonergic effects, neuroplasticity, and anti-inflammatory effects, suggesting further research into psychedelics for olfactory dysfunction.

Published
August 31, 2023
Journal
Journal of Psychoactive Drugs
Authors
Kovacevich, A., Weleff, J., Claytor, B., Barnett, B. S.
Open Accessindividual

Ayahuasca in the treatment of bipolar disorder with psychotic features-A retrospective case study

This retrospective case study describes a woman with bipolar disorder and psychotic features whose suicidality, dissociation and social isolation markedly improved and were sustained after multiple ayahuasca ceremonies, with corroboration of childhood abuse and ongoing symptom reduction over several years. The report suggests potential therapeutic benefits of ayahuasca for severe traumatisation and bipolar symptoms and situates the case within a brief review of low‑dose ayahuasca and LSD treatment literature.

Published
March 10, 2023
Journal
Psyarxiv
Authors
Turkia, M.
Open Accessindividual

Classic psychedelics do not affect T cell and monocyte immune responses

In vitro exposure to LSD, psilocin, DMT and mescaline did not alter proliferation or stimulated cytokine release of primary human T lymphocytes nor induce NF-κB in monocytes. These results indicate classic psychedelics do not directly modulate key T‑cell or monocyte functions and support their safe use in assisted psychotherapy where immune suppression would be detrimental.

Published
January 20, 2023
Journal
Frontiers in Psychiatry
Authors
Rudin, D., Areesanan, A., Liechti, M. E., Gründemann, C.
Paywallindividual

LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility

This trial (n=24) investigated the effects LSD (50 μg) has on cognition in healthy volunteers. It was found that LSD sub-acutely improved visuospatial memory and phonological verbal fluency and impaired cognitive flexibility when compared to placebo.

Published
May 1, 2022
Journal
European Neuropsychopharmacology
Authors
Wießner, I., Olivieri, R., Falchi, M., Palhano-Fontes, F., Maia, L. O., Feilding, A., Araújo, D. B., Ribeiro, S., Tófoli, L.F.
Paywallindividual

5-HT2CR Is as Important as 5-HT2AR in Inducing Hallucinogenic Effects in Serotonergic Compounds

This rodent study (2022) shows that the activation of serotonin receptors (5-HT) by mescaline derivatives via 5-HT2CR, alone or in concert with 5-HT2AR, produces comparable hallucinogenic effects to activation via divergent 5-HT2CR- and/or 5-HT2AR signalling pathways. Given that many believe 5-HT2AR activation is the route through which psychedelics exert their effects, these findings show that 5-HT2CR is as important as 5-HT2AR in inducing these effects.

Published
January 1, 2022
Journal
SSRN
Authors
James Perez Custodio, R., Ortiz, D. M., Lee, H. J., Sayson, L. V., Buctot, D., Kim, M., Lee, Y. S., Kim, K. M., Cheong, J. H., Kim, H. J.
Open Accessindividual

LSD-stimulated behaviors in mice require β-arrestin 2 but not β-arrestin 1

This mice study finds that, using mice with specific receptor deficiencies, the signals are β-arrestin-2 (βArr; type of protein important in signalling) mediated, but not βarr1 mediated. This line of evidence points towards the requirement of βArr2 for LSD's psychedelic effects.

Published
September 3, 2021
Journal
Scientific Reports
Authors
Rodriguiz, R. M., Nadkarni, V., Means, C. R., Pogorelov, V. M., Chiu, Y. T., Roth, B. L., Wetsel, W. C.

Clinical Trials

0 trials

No clinical trials have been tagged with both LSD and Immunology & Inflammation yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all LSD papers Search all Immunology & Inflammation trials Full LSD profile Full Immunology & Inflammation profile